Logo

454 CEO Lands at Ensemble as CuraGen CEO Steps Down

Apr 06, 2005

NEW YORK, April 6 (GenomeWeb News) - CuraGen, the parent company of 454 Life Sciences, this week said that CEO Jonathan Rothberg will be stepping down.

 

In a separate announcement, Ensemble Discovery said it has hired former 454 president and CEO Richard Begley as its new president and CEO.

 

New Haven, Conn.-based CuraGen said it has begun to look for a new CEO, and that Rothberg will remain in his position until a replacement is appointed. Rothberg has been the chairman and CEO of the pharmaceutical company since it was founded seven years ago.

 

According to CuraGen, Patrick Zenner, a member of the board of directors, has been asked to chair the search committee for the new CEO, and Rothberg said in a statement that he would assist in the search.

Breaking News
The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.